Oramed Pharmaceuticals, Inc
ORMP - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$158.42M
Close$
$0.98
74.5% downside
Current Fair Value
74.5% downsideOvervalued by 74.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $158.42 Million |
|---|---|
| Enterprise Value | $145.61 Million |
| Annual dividend | $0.25 |
| Dividend yield | 6.48% |
| Earnings per Share | $1.53 |
| Beta | 1.28 |
| Outstanding Shares | 41,040,479 |
Return
| Return on Equity | 58.63% |
|---|---|
| Return on Assets | 58.86% |
| Return on Invested Capital | 25.49% |
Valuation & Multiples
| P/E Ratio | 0.91 |
|---|---|
| PEG | 0.19 |
| Price to Sales | - |
| Price to Book Ratio | 0.64 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 1.87 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$0.15
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$0.43
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.50%▼ 40.58% |
|---|---|
| Total Invested | $949,768▼ 98.83% |
| Investors Holding | 7▼ 79.00% |
About Oramed Pharmaceuticals, Inc
13 employees
CEO: Nadav Kidron
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase I...